Claims of Gene-Edited Twins Met with Criticism and Concern

BIOtech Now
Andrew Segerman

As the Second International Summit on Human Genome Editing wraps in Hong Kong this week, breaking news dominated much of the conversation.

Specifically, a Chinese scientist claims to have used CRISPR-Cas9 — the groundbreaking genome editing technology — to tweak the DNA of human embryos, which resulted in the birth of twin girls.

The news was met with criticism from stakeholders across the health care spectrum, which included deep concerns from the biopharmaceutical industry.  Yesterday, BIO issued the following statement on the news:

“While we still are waiting for the full facts of this story to come to light and be independently verified, we found the human genome editing activity by an individual scientist out of China, as described in press reports, to be deeply troubling if true. Any human germline experimentation of this kind would be irresponsible.  BIO and its member companies view the science of genome editing as having not advanced sufficiently for clinical applications involving potentially heritable human genetic changes to be appropriate, and such activity is prohibited in the United States. It is vital that extensive discussions and engagement continue to take place among all major stakeholders, including members of the scientific, patient, caregiver, policy, legal, ethical, and faith communities, to determine whether, and under which conditions, germline genome editing should take place for human clinical application.

“Accordingly, BIO member companies involved in human genome editing are focused on using gene editing technologies for clinical applications on somatic (non-heritable) cellular therapies designed to treat patients currently suffering from devastating genetic diseases.  We support the robust U.S. regulatory framework that oversees clinical use of genome editing in non-heritable cells, which is similar to that of other advanced biotherapeutic technologies such as gene therapy. BIO also has an established working group of member companies involved in genome editing, which is leading our efforts to develop appropriate policies for this evolving technology and to engage in dialogue with relevant stakeholders on its benefits and responsible application.

“BIO strongly condemns any actions in violation of laws and regulations. BIO and scientific leaders across the globe stand united in calling upon policymakers and the scientific community around the world to set, follow, and enforce guidelines and policies for the responsible application of human genome editing technology in their respective countries.”

Genome editing, when properly used, represents one of the most promising areas of biotechnology, with the potential to produce transformative breakthroughs in both human health and agriculture.

For important resources and background materials to better understand these groundbreaking innovations and what is needed to ensure that society can harness the full potential of this remarkable technology, head over to

Full BIOtech Now Article here

Powered by WPeMatico